Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 2004

View Archived Issues

LifeSciChannel.com interviews Kalypsys at BIO-Europe 2004

Jak-Stat inhibitor shows promise for the treatment of AML

Toll-like receptor agonist may be an effective immunotherapeutic approach to CLL

Antibody therapy may enhance rituximab-mediated killing in non-Hodgkin's lymphoma

Bionomics receives START grant extension for breast cancer efforts

TS-041 enters phase I study

New conjugate carrier for effective antitumor boron neutron capture therapy

Medicis gains access to Ansata antimicrobial peptide technology

Axaminer demonstrates capabilities in studies

Vion updates phase II Triapine-gemcitabine study in pancreatic cancer

Procyon files IND for PCK-3145

Trillium and Genentech enter global license agreement

Abbott submits Xinlay NDA for metastatic hormone-refractory prostate

Aphton to acquire Igeneon

Aventis scientists prepare and test new oncolytic agents

Schering-Plough claims gamma-secretase inhibitors

Topical formulation for delivery of TRPVI agonists

Combination of CNS stimulant and opioid antagonist covered in Euroceltique patent

Pfizer researchers describe new renin inhibitors for hypertension

NicOx prepares for phase III program of HCT-3012

Two new series of muscarinic receptor antagonists designed at Ranbaxy

Brain tumor compound ECO-4601 enters pharmacology and toxicology trials

Retisert NDA accepted for review

Lunesta approved for treatment of insomnia

Zylet receives FDA approval

Phase III trial and other results for decitabine presented at ASH meeting

BMS-354825 demonstrates activity in resistant chronic myeloid leukemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...